Browse the evidence

Deprescribing GLP-1 agonists in patients with Type 2 Diabetes does not result in weight regain or loss of glycemic control if the patient maintains Carbohydrate Restricted Nutrition Therapy (CRNT) supported by continuous remote care.

If you are taking a GLP-1 drug (like Ozempic or Wegovy) for Type 2 Diabetes, you may be able to stop the medication without regaining weight or losing blood sugar control, provided you switch to a strict low-carbohydrate diet (under 30g carbs/day) and maintain nutritional ketosis. This approach mimics the drug's hormonal effects on hunger and satiety. You should work with a healthcare provider to monitor your progress and determine if you are a candidate for deprescription.

Carbohydrate Restricted Nutrition Therapy (CRNT) induces hormonal changes (lower ghrelin, higher GLP-1/CCK) that reduce hunger and appetite, thereby supporting weight maintenance after GLP-1 deprescription.

The reason low-carb diets help you stay full is not just willpower; they biologically alter your hunger hormones. Ketosis lowers ghrelin (the hunger hormone) and increases satiety hormones, making it easier to maintain weight loss without constant hunger.

GLP-1 receptor agonists (liraglutide, semaglutide) and dual GLP-1/GIP agonists (tirzepatide) are the most promising pharmacological treatments for obesity in older adults, offering favorable efficacy and safety profiles, though specific guidelines are currently lacking.

For older adults with obesity, GLP-1 agonists like liraglutide and semaglutide are currently the most effective pharmacological options. They work by mimicking hormones that regulate appetite and blood sugar. While they cause significant weight loss, there is a risk of muscle loss, so these medications should ideally be used alongside resistance exercise and adequate protein intake. Start with a low dose and increase slowly to manage stomach side effects. Note that data for those over 75 is limited.

Intraweek Training Monotony (ITM) and Acute:Chronic Workload Index (ACWI) provide distinct, non-redundant information compared to Foster's Training Monotony and Acute:Chronic Workload Ratio (ACWR) by incorporating load orientation, session duration, and weekly density.

Use ITM to monitor variety within a single week and ACWI to track workload trends over the season. Unlike standard metrics that only look at volume and intensity, these indices also account for what type of training (technical, tactical, physical) is being performed. This helps identify if a player is doing similar work repeatedly (high monotony) or varying loads effectively, allowing for more personalized adjustments.

In patients with type 2 diabetes, a lifestyle pattern characterized by evening chronotype, poor sleep quality, and depressive status is associated with higher HbA1c, systolic blood pressure, and arterial stiffness (baPWV).

If you have type 2 diabetes, your sleep schedule and mental health are not just lifestyle details—they are critical metabolic drivers. Prioritizing consistent sleep times, addressing depression, and avoiding late-night eating can directly improve your blood sugar control and heart health.

A lifestyle pattern characterized by high physical activity is associated with lower uric acid levels in T2DM patients, despite potentially elevated liver enzymes.

High physical activity in T2DM patients is linked to lower uric acid, which is beneficial. However, it may also be associated with elevated liver enzymes. A balanced approach addressing sleep, diet, and alcohol is more critical for overall health than exercise alone.

Simplified, quality-focused diet logging (tracking food categories like fruits, vegetables, and whole grains without caloric quantification) significantly improves dietary scores and reduces cardiovascular risk scores, even when users do not actively monitor their risk feedback.

Stop trying to count every calorie. Instead, use a simple app to track whether you are eating specific healthy food groups (like fruits, vegetables, and whole grains) and avoiding unhealthy ones (like sugary drinks and processed meats). Do this daily. You do not need to obsess over the risk score displayed by the app, as the act of logging these quality choices alone is enough to improve your diet and long-term heart health.

Two weeks of combined energy restriction and severe step reduction (<750 steps/day) causes a significant reduction in whole-muscle isometric strength (MVC) in healthy older adults, but this loss is not explained by changes in single muscle fiber contractile function, which instead shows increased power and tension.

If you are an older adult and must reduce your activity due to illness or injury, expect your maximum strength to drop slightly after two weeks. However, do not panic: your muscle fibers may actually become more efficient (producing more power/tension) to compensate. Most importantly, if you maintain high protein intake, your strength is likely to recover once you resume normal activity, especially for men. Women may take longer to recover strength, so a gradual return to activity is advised.

Older women fail to recover whole-muscle isometric strength after resuming normal activity following a period of combined energy restriction and step reduction, whereas older men fully recover their baseline strength.

If you are an older woman recovering from a period of reduced activity or illness, be aware that your maximum strength might not bounce back as quickly as a man's, even if you return to normal activity. You may need to focus on gradual strength retraining rather than just resuming normal daily activities to regain lost muscle function.

Five weeks of campus board training improves climbing-specific performance, but optimal frequency depends on the specific outcome: two sessions per week maximize bouldering performance, while four sessions per week maximize rate of force development (RFD).

If you are an advanced climber using a campus board, split your weekly volume into 4 shorter sessions to boost explosive power (RFD). If your goal is bouldering performance specifically, 2 sessions per week may be sufficient and potentially more effective for that specific outcome, provided you maintain maximal intensity.

Five weeks of campus board training improves maximal force in large holds (jugs) and rate of force development (RFD) in advanced climbers, but does not significantly increase maximal finger strength on small holds (rungs) or arm circumference in this short timeframe.

Don't expect significant finger strength gains on small holds from just 5 weeks of campus board training. Instead, focus on the explosive power (RFD) and strength on larger holds (jugs) which this training effectively improves.

Dietary intervention (weight loss maintenance) increases circulating Heme-oxygenase-1 (HO-1) levels, with a non-significant trend toward greater increases on Low Glycemic Index diets.

Weight loss maintenance increases HO-1, an enzyme that may help reduce oxidative stress. While the type of diet matters less for HO-1, Low Glycemic Index diets showed a trend toward higher increases. This is a minor benefit of weight loss.

Oral semaglutide administration in patients with type 2 diabetes significantly reduces body weight, HbA1c, and total cholesterol within 3-6 months, with additional systolic blood pressure reduction observed by 6-12 months.

If you have Type 2 Diabetes, oral semaglutide can significantly improve your weight, blood sugar (HbA1c), and cholesterol levels within the first 6 months, with blood pressure improvements continuing up to a year. While gastrointestinal side effects like nausea are common and may lead some to stop the medication, serious safety issues were not observed in this real-world study. It serves as a viable alternative to injectable GLP-1s, particularly for those who prefer oral medication or have needle phobia.

Athletes and active individuals prioritize 'enhanced muscular recovery' as the primary claim for sports nutrition products, with 25% ranking it first and 73% in their top three priorities.

If you are an athlete looking for sports nutrition products, prioritize those that explicitly support muscle recovery. Look for whole-food-based options rather than just supplements, as this is the most desired feature for this group. Ensure the product has scientific backing, as 87% of users rate scientific proof as important.

Athletes and active individuals prefer whole food nutritional products over supplements, powders, or bars for both performance and recovery.

When choosing sports nutrition products, look for whole food options rather than isolated supplements or powders. This format is preferred by athletes for both performance and recovery. Ensure the product is scientifically proven, as this is a key factor for 87% of users.

Nutritional profile is the most important attribute for purchasing sports nutrition products, followed by taste and accessibility.

When selecting sports nutrition products, prioritize those with a clear and beneficial nutritional profile. Taste and accessibility are also important secondary factors. Ensure the product has scientific proof, as this is highly valued.

Technology-assisted weight management interventions utilizing the 5As behavioral model (Assess, Advise, Agree, Assist, Arrange) can facilitate effective primary care counseling and goal setting without overburdening healthcare providers.

For veterans or primary care patients, using a structured, technology-assisted counseling model (like the 5As) can make weight management support more accessible and less stressful. The key is combining a user-friendly digital tool for self-assessment and goal setting with human support from a health coach who helps refine goals and address barriers. This approach reduces the burden on busy doctors and ensures patients receive consistent, personalized feedback without feeling judged.

GLP-1 receptor agonists may improve psoriasis symptoms (PASI score) in patients with Type 2 Diabetes, though evidence from randomized controlled trials is mixed.

If you have psoriasis and Type 2 Diabetes, GLP-1 medications might help improve your skin symptoms, but this is not guaranteed. The most reliable benefit is the protection against heart disease and stroke. Discuss with your doctor if the potential skin benefits, combined with cardiovascular protection, outweigh the need for an injection.

Once-weekly subcutaneous administration of the glucagon/GLP-1 receptor co-agonist NNC9204-1177 produces dose-dependent, clinically significant body weight loss in adults with overweight or obesity, but is associated with unacceptable safety concerns including increased heart rate, hepatic disturbances, and impaired glucose tolerance.

This specific drug (NNC9204-1177) is not available for clinical use because it caused unacceptable side effects like increased heart rate and liver issues, despite causing significant weight loss. However, it highlights that combining GLP-1 and glucagon pathways can lead to substantial weight loss, which is why other approved GLP-1 medications exist. If you are considering GLP-1 therapy, discuss the specific safety profile of the approved options with your healthcare provider.

Oral semaglutide (up to 7 mg/day) produces significant weight loss (mean 4.5 kg) and BMI reduction in psychiatric patients with antipsychotic-induced weight gain over 16 weeks, with a safety profile comparable to metformin.

For psychiatric patients struggling with weight gain from antipsychotics, oral semaglutide is a viable treatment option. Start with 3 mg daily for the first month, then increase to 7 mg daily if tolerated. Expect about 4.5 kg (10 lbs) of weight loss over 4 months. Side effects like nausea are common but usually mild and go away. This treatment does not worsen psychiatric symptoms and may even improve quality of life.

Combined blockade of GDF8 (myostatin) and Activin A using monoclonal antibodies significantly increases lean muscle mass and decreases fat mass in postmenopausal women, with effects reversing to baseline upon cessation of treatment.

For postmenopausal women seeking to increase muscle mass, blocking both myostatin and activin A via antibody therapy produces significant muscle growth and fat loss. However, this effect is not permanent; stopping treatment leads to a return to baseline muscle size within about 6 months. The treatment requires regular IV infusions and carries mild side effects like muscle spasms. It is not a lifestyle intervention but a medical therapy requiring clinical supervision.

High-intensity interval training (HIIT) or resistance training (RT) is safe and effective for patients with muscle Carnitine Palmitoyl-Transferase II (CPTII) deficiency because these activities rely on glycogen/phosphocreatine pathways rather than long-chain fatty acid oxidation, thereby avoiding rhabdomyolysis triggers.

If you have CPTII deficiency, do not avoid exercise entirely. Instead of long, steady-state cardio (like running or cycling) which relies on fat burning, focus on resistance training and high-intensity intervals (like sprints or circuit training). These activities use glycogen, which your muscles can still process safely. Start with moderate intensity (around 70% of your max capacity) and build up gradually under supervision.

In carriers of the BDNF rs10835211 GG genotype, high carbohydrate intake (>48% of energy) is associated with lower fat-free mass and skeletal muscle mass compared to lower intake, whereas high fiber intake (>18g/day) is associated with higher fat-free mass but also higher total cholesterol and LDL-C.

If you carry the BDNF rs10835211 GG genotype, your body composition response to macronutrients differs from the general population. High carbohydrate intake (>48% of calories) may be associated with lower muscle mass in this group. However, ensuring adequate fiber intake (>18g/day) may support higher fat-free mass, though it was also linked to higher cholesterol in this specific study. Focus on fiber-rich carbohydrate sources and monitor lipid profiles.

In BDNF rs10835211 GG genotype carriers, high protein intake (>18% of energy) is associated with higher waist circumference, BMI, body fat, and insulin resistance (HOMA-IR), while high fat intake (>30% of energy) is associated with higher visceral adipose tissue (VAT) and HDL-C.

If you carry the BDNF rs10835211 GG genotype, be cautious with high-protein (>18% energy) and high-fat (>30% energy) diets. This study links these intake levels in this group to higher waist circumference, visceral fat, and insulin resistance. Consider balancing these macros and monitoring waist circumference and fasting insulin.